aid: aiolos-bio
name: Aiolos Bio
description: >-
  Aiolos Bio was a clinical-stage biopharmaceutical company founded in 2023 with offices in San
  Francisco, California and London, United Kingdom, developing treatments for respiratory and
  inflammatory disease. Its sole disclosed asset was AIO-001, a half-life-extended monoclonal
  antibody against thymic stromal lymphopoietin (TSLP), positioned as a Phase 2-ready candidate
  for moderate-to-severe asthma with potential six-month dosing intervals. The company launched
  in October 2023 with an oversubscribed $245 million Series A co-led by Atlas Venture, Bain
  Capital Life Sciences, Forbion and Sofinnova Investments, with RA Capital Management. GSK plc
  agreed to acquire it on 9 January 2024 for $1 billion upfront plus up to $400 million in
  milestones, completing on 14 February 2024. Aiolos Bio is a drug developer, not a software
  vendor: it never ran a developer program, public API, SDK or machine-readable contract, and
  aiolosbio.com now serves a blanket HTTP 301 to www.gsk.com on every path.
url: https://raw.githubusercontent.com/api-evangelist/aiolos-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-source-url: https://forgeglobal.com/aiolos-bio_stock/
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-14'
modified: '2026-09-14'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Pharmaceuticals
- Drug Development
- Clinical Trials
- Respiratory
- Immunology
- Monoclonal Antibodies
- Life Sciences
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://aiolosbio.com/
- type: LinkedIn
  url: https://www.linkedin.com/company/aiolos-bio
- type: SecondaryMarket
  url: https://forgeglobal.com/aiolos-bio_stock/
- type: DomainSecurity
  url: security/aiolos-bio-domain-security.yml
x-enrichment:
  date: '2026-09-14'
  status: minimal
  artifacts_added: 2
  pass: local-v3
x-coverage:
  state: none
  reason: defunct
  detail: >-
    Aiolos Bio was a clinical-stage asthma-antibody developer that ceased to exist as an
    independent company when GSK completed its acquisition on 2024-02-14, and its domain
    aiolosbio.com now answers every path — including /.well-known/security.txt, /openapi.json and
    /llms.txt — with a blanket HTTP 301 to https://www.gsk.com/, while api., docs., developer. and
    portal.aiolosbio.com are all NXDOMAIN, so there is no surviving host, developer program or
    contract to profile.
  evidence:
  - url: https://aiolosbio.com/.well-known/security.txt
    status: 301
  - url: https://aiolosbio.com/openapi.json
    status: 301
  - url: https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-aiolos-bio/
    status: 200
  - url: https://forgeglobal.com/aiolos-bio_stock/
    status: 403
  checked: '2026-09-14'